At CDMO Live 2025 external manufacturing leaders from Bayer, Boehringer Ingelheim, and Leo Pharma revealed how pharmaceutical companies are adapting their manufacturing networks amid growing global uncertainty. The panel, sponsored by Blue Jet Healthcare, highlighted portfolio complexity and geopolitical tensions
Aldevron, a global supplier of DNA, RNA, and protein, and Integrated DNA Technologies (IDT), a genomics solutions provider, have announced the successful production of the first personalised CRISPR gene editing drug for a paediatric patient with urea cycle disorder. Developed in partnership
Cybin Inc., a clinical-stage neuropsychiatry company, has announced a manufacturing partnership with Thermo Fisher Scientific to support the advancement of CYB003, its proprietary deuterated psilocin therapy for Major Depressive Disorder (MDD). The agreement covers Phase 3 clinical supply and potential
SK pharmteco, a global contract development and manufacturing organisation (CDMO), has expanded its stability storage capabilities at its El Dorado Hills site in California. The new validated chambers increase storage capacity by 40% and are designed to meet rising demand
Kincell Bio, a cell therapy development and manufacturing company, has closed a $22 million funding round to accelerate its growth as a CDMO for advanced therapies. The investment was led by NewSpring Capital through its NewSpring Healthcare strategy, alongside continued
AGC Biologics has announced a new partnership with Quell Therapeutics, a clinical-stage biotechnology company developing T-regulatory (Treg) cell therapies for severe immune disorders. The collaboration will see AGC Biologics supply lentiviral vector (LVV) material using its proprietary ProntoLVV™ platform to support
Skyepharma has marked six months of activity at its MMPP (Medicines to be Handled with Particular Care) facility, dedicated to the development and production of high-potency oral oncology drugs. The French CDMO has shared early achievements from the site, located in
TriLink BioTechnologies, a Maravai LifeSciences company, has signed a Memorandum of Understanding with the International Vaccine Institute (IVI) to explore joint initiatives in mRNA vaccine research, development, and equitable distribution. The agreement sets the foundation for discussions on collaborative models,
3PBIOVIAN, a CDMO partner in biopharmaceutical manufacturing, has announced the launch of its AAVion Platform—an end-to-end adeno-associated virus (AAV) manufacturing solution aimed at accelerating gene therapy development. The platform is now available to biotech and pharmaceutical companies globally. The AAVion
Terumo Corporation has announced a €150 million agreement to acquire WuXi Biologics’ drug product (DP) manufacturing plant located in Leverkusen, Germany. The facility will serve as Terumo’s first overseas base for its contract development and manufacturing organisation (CDMO) business. The site
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
